Skip to main content
Company profile
PureTech Health PLC logo

PureTech Health PLC

Pipeline5 assets

  • deupirfenidoneLYT-100 / Small Molecule / Respiratory / Fibrotic Diseases
    Idiopathic Pulmonary Fibrosis (IPF)Phase 3ActiveGlobal
  • LYT-200LYT-200 / Biologic / Oncology
    Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)Phase 1ActiveGlobalSolid TumorsPhase 1ActiveGlobal
  • GlyphAlloSPT-300 / Allopregnanolone / Small Molecule / Neuropsychiatry
    Anxiety and Mood DisordersPhase 2ActiveGlobal
  • GlyphAgoSPT-320 / Small Molecule / Neuropsychiatry
    Neurological / Neuropsychiatric IndicationsPhase 1ActiveGlobal
  • xanomeline and trospium chlorideKarXT / Cobenfy / Muscarinic Receptors / Small Molecule / Neuropsychiatry
    SchizophreniaApprovedActiveUS

Latest news16 items

All news

PureTech Health plc – Half-Year Report

RNS Number: 6717V PureTech Health PLC 22 September 2026 22 September 2026 PureTech Health plc - Half-Year Report Delivered significant progress across the portfolio, including Seaport's Nasdaq IPO, Celea's financing and Phase 3 trial initiation, and Gallop's positive Phase 1b data, successful

PureTech Announces Successful End-of-Phase 1 Meeting with U.S . Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

RNS Number: 4709V PureTech Health PLC 21 September 2026 21 September 2026 PureTech Health plc PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic

Trial Results • Phase 1Phase 1b topline data Mon, Sep 21, 2026

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

RNS Number: 1273U PureTech Health PLC 09 September 2026 9 September 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

Trial Results • Phase 1Topline results Wed, Sep 9, 2026

Notice of Half-Yearly Results

RNS Number: 4123T PureTech Health PLC 04 September 2026 4 September 2026 PureTech Health plc Notice of Half-Yearly Results PureTech Health plc (LSE: PRTC) (" PureTech " or the "Company") plans to announce its half-yearly results for the six months ended 30 June 2026 on Tuesday 22 September 2026.

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

RNS Number: 0041S PureTech Health PLC 25 August 2026 25 August 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress Presentations will highlight Celea's differentiated approach to

Presentation / Abstract • Phase 1ERS oral presentation Mon, Sep 7, 2026, 11:05 AM CEST

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

RNS Number: 0542M PureTech Health PLC 13 July 2026 13 July 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) SURPASS-IPF is the

Trial Start • Phase 3Trial initiation Mon, Jul 13, 2026

Results of Annual General Meeting

RNS Number: 8399H PureTech Health PLC 10 June 2026 10 June 2026 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (LSE: PRTC) (" PureTech " or the "Company") was held at 11 a.m. EDT / 4 p.m. BST on Wednesday, June 10, 2026.

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

RNS Number: 5025H PureTech Health PLC 09 June 2026 9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

Trial Results • Phase 1Results event Mon, Jun 8, 2026

PureTech Announces Annual Results for Year Ended December 31, 2025

RNS Number: 2953C PureTech Health PLC 29 April 2026 29 April 2026 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2025 Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

RNS Number: 4332B PureTech Health PLC 22 April 2026 22 April 2026 PureTech Health plc PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Phase 1b dataset with

Trial Results • Phase 1
PureTech Health PLC • Endpoint Arena